[go: up one dir, main page]

MX2008013635A - Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. - Google Patents

Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.

Info

Publication number
MX2008013635A
MX2008013635A MX2008013635A MX2008013635A MX2008013635A MX 2008013635 A MX2008013635 A MX 2008013635A MX 2008013635 A MX2008013635 A MX 2008013635A MX 2008013635 A MX2008013635 A MX 2008013635A MX 2008013635 A MX2008013635 A MX 2008013635A
Authority
MX
Mexico
Prior art keywords
patients suffering
drug
cognitive disorders
preparation
treatment
Prior art date
Application number
MX2008013635A
Other languages
English (en)
Inventor
Roura Victor Grifols
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of MX2008013635A publication Critical patent/MX2008013635A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se basa en la utilización de albúmina humana terapéutica para la preparación de un medicamento para el tratamiento de pacientes afectados por desórdenes cognitivos, en la que el modelo de administración del medicamento comprende la administración al paciente de un mínimo de tres veces sucesivas, de una cantidad terapéuticamente efectiva de albúmina terapéutica humana mediante recambio plasmático y/o perfusión intravenosa, sin dependencia del contenido de Aß en sangre del paciente.
MX2008013635A 2007-10-26 2008-10-23 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. MX2008013635A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702831A ES2332846B1 (es) 2007-10-26 2007-10-26 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.

Publications (1)

Publication Number Publication Date
MX2008013635A true MX2008013635A (es) 2009-05-11

Family

ID=40583637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013635A MX2008013635A (es) 2007-10-26 2008-10-23 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.

Country Status (16)

Country Link
US (1) US7851446B2 (es)
EP (1) EP2111868B1 (es)
JP (1) JP5437619B2 (es)
CN (1) CN101417123B (es)
AR (1) AR068901A1 (es)
AU (1) AU2008233025B8 (es)
BR (1) BRPI0804623B8 (es)
CA (1) CA2641830C (es)
CL (1) CL2008003133A1 (es)
ES (2) ES2332846B1 (es)
MX (1) MX2008013635A (es)
NZ (1) NZ572131A (es)
PL (1) PL2111868T3 (es)
PT (1) PT2111868E (es)
RU (1) RU2414925C2 (es)
UY (1) UY31418A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
CA3033051A1 (en) * 2016-08-18 2018-02-22 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP4299129A3 (en) * 2017-04-26 2024-03-20 Alkahest, Inc. Dosing regimen for treatment of cognitive impairments with blood plasma products
MX2021000707A (es) * 2018-07-20 2021-03-25 Alkahest Inc Regimen de dosificacion para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
EP3643319A1 (en) * 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
WO2020086469A1 (en) 2018-10-26 2020-04-30 Alkahest, Inc. Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
JP2023547479A (ja) * 2020-10-30 2023-11-10 シェンチェン、プロトゲン、リミテッド 疾患の治療におけるヒト血清アルブミンの使用
CA3215030A1 (en) * 2021-04-30 2022-11-03 Victor Grifols Roura Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612137A1 (de) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5112298A (en) 1990-06-25 1992-05-12 Baxter International Inc. Apheresis method and device
US5178603A (en) 1990-07-24 1993-01-12 Baxter International, Inc. Blood extraction and reinfusion flow control system and method
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
CA2408566A1 (en) 2000-05-23 2001-11-29 Berislav V. Zlokovic Role of ldl receptor protein-1 (lrp-1) in alzheimer's disease
WO2002078670A1 (en) * 2001-03-02 2002-10-10 Neuron Therapeutics, Inc. Neuroprotectants formulations and methods
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
JP4690043B2 (ja) 2002-10-04 2011-06-01 プラナ バイオテクノロジー リミティッド 神経に対し活性な化合物
US20070010435A1 (en) 2002-12-19 2007-01-11 New York University Method for treating amyloid disease
KR20050103292A (ko) 2003-02-13 2005-10-28 옥타파르마 아게 알부민 용액 및 이의 제조 방법
US20050042284A1 (en) 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
RU2261702C1 (ru) * 2004-09-23 2005-10-10 Смирнов Алексей Владимирович Способ лечения гипергомоцистеинемии у больных с хронической почечной недостаточностью, получающих лечение гемодиализом или гемофильтрацией
RU2281090C2 (ru) * 2004-09-23 2006-08-10 Алексей Владимирович Смирнов Способ лечения больных хронической почечной недостаточностью
US7436304B1 (en) 2005-07-19 2008-10-14 Visible Assets, Inc Evidence tracking

Also Published As

Publication number Publication date
ES2428698T3 (es) 2013-11-08
ES2332846A1 (es) 2010-02-12
RU2008141076A (ru) 2010-04-27
JP5437619B2 (ja) 2014-03-12
HK1126689A1 (en) 2009-09-11
CA2641830A1 (en) 2009-04-26
EP2111868B1 (en) 2013-08-21
UY31418A1 (es) 2009-05-29
AU2008233025B8 (en) 2013-07-25
CA2641830C (en) 2013-07-16
CN101417123A (zh) 2009-04-29
PT2111868E (pt) 2013-10-17
NZ572131A (en) 2010-06-25
BRPI0804623B8 (pt) 2021-05-25
AU2008233025B2 (en) 2013-06-27
US7851446B2 (en) 2010-12-14
CN101417123B (zh) 2012-06-27
ES2332846B1 (es) 2010-07-08
US20090111740A1 (en) 2009-04-30
BRPI0804623A2 (pt) 2009-06-30
EP2111868A1 (en) 2009-10-28
RU2414925C2 (ru) 2011-03-27
AR068901A1 (es) 2009-12-16
JP2009108059A (ja) 2009-05-21
BRPI0804623B1 (pt) 2020-02-11
AU2008233025A1 (en) 2009-05-14
PL2111868T3 (pl) 2014-01-31
CL2008003133A1 (es) 2009-08-07

Similar Documents

Publication Publication Date Title
MX2008013635A (es) Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
JP2022009125A5 (es)
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
JP6673924B2 (ja) 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
UA81573C2 (en) Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients
WO2008067991A3 (en) Skin-friendly drug complexes for transdermal administration
MY135838A (en) Methods for the treatment of mental disorders
RU2012108656A (ru) Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы
SE0400184D0 (sv) New therapeutical use
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
EP1728076A4 (en) SYSTEM AND METHOD FOR PROVIDING OPTIMUM CONCENTRATIONS FOR MEDICAMENT INFUSIONS
DK1289535T3 (da) Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme
DE602007014193D1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
IL173822A0 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
NZ597957A (en) Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations

Legal Events

Date Code Title Description
FG Grant or registration